Management of severe acute respiratory distress syndrome in Australia and New Zealand (SAGE-ANZ): An observational study
- PMID: 39355498
- PMCID: PMC11440055
- DOI: 10.1016/j.ccrj.2024.05.001
Management of severe acute respiratory distress syndrome in Australia and New Zealand (SAGE-ANZ): An observational study
Abstract
Objective: Acute respiratory distress syndrome (ARDS) is associated with significant mortality, morbidity, and cost. We aimed to describe characteristics and management of adult patients admitted to intensive care units (ICUs) in Australia and New Zealand with moderate-severe ARDS, to better understand contemporary practice.
Design: Bi-national, prospective, observational, multi-centre study.
Setting: 19 ICUs in Australia and New Zealand.
Participants: Mechanically ventilated patients with moderate-severe ARDS.
Main outcome measures: Baseline demographic characteristics, ventilation characteristics, use of adjunctive support therapy and all-cause mortality to day 28. Data were summarised using descriptive statistics.
Results: 200 participants were enrolled, mean (±SD) age 55.5 (±15.9) years, 40% (n = 80) female. Around half (51.5%) had no baseline comorbidities and 45 (31%) tested positive for COVID-19. On day 1, mean SOFA score was 9 ± 3; median (IQR) PaO2/FiO2 ratio 119 (89, 142), median (IQR) FiO2 70% (50%, 99%) and mean (±SD) positive end expiratory pressure (PEEP) 11 (±3) cmH2O. On day one, 10.5% (n = 21) received lung protective ventilation (LPV) (tidal volume ≤6.5 mL/kg predicted body weight and plateau pressure or peak pressure ≤30 cm H2O). Adjunctive therapies were received by 86% (n = 172) of patients at some stage from enrolment to day 28. Systemic steroids were most used (n = 127) followed by neuromuscular blockers (n = 122) and prone positioning (n = 27). Median ventilator-free days (IQR) to day 28 was 5 (0, 20). In-hospital mortality, censored at day 28, was 30.5% (n = 61).
Conclusions: In Australia and New Zealand, compliance with evidence-based practices including LPV and prone positioning was low in this cohort. Therapies with proven benefit in the treatment of patients with moderate-severe ARDS, such as lung protective ventilation and prone positioning, were not routinely employed.
Keywords: Acute respiratory distress syndrome: adjunctive therapy; Lung protective ventilation; Mechanical ventilation; Prone positioning.
© 2024 The Authors.
Figures
Similar articles
-
Management of Acute Respiratory Distress Syndrome and Refractory Hypoxemia. A Multicenter Observational Study.Ann Am Thorac Soc. 2017 Dec;14(12):1818-1826. doi: 10.1513/AnnalsATS.201612-1042OC. Ann Am Thorac Soc. 2017. PMID: 28910146
-
Variation in Early Management Practices in Moderate-to-Severe ARDS in the United States: The Severe ARDS: Generating Evidence Study.Chest. 2021 Oct;160(4):1304-1315. doi: 10.1016/j.chest.2021.05.047. Epub 2021 Jun 4. Chest. 2021. PMID: 34089739 Free PMC article.
-
Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.Lancet Respir Med. 2021 Sep;9(9):989-998. doi: 10.1016/S2213-2600(21)00229-0. Epub 2021 Jul 2. Lancet Respir Med. 2021. PMID: 34224674 Free PMC article.
-
Respiratory Subsets in Patients with Moderate to Severe Acute Respiratory Distress Syndrome for Early Prediction of Death.J Clin Med. 2022 Sep 27;11(19):5724. doi: 10.3390/jcm11195724. J Clin Med. 2022. PMID: 36233592 Free PMC article. Review.
-
Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment.JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. JAMA. 2018. PMID: 29466596 Review.
References
-
- Bersten A.D., Edibam C., Hunt T., Moran J., Australian and New Zealand Intensive Care Society Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. Am J Respir Crit Care Med. Feb 15 2002;165(4):443–448. doi: 10.1164/ajrccm.165.4.2101124. - DOI - PubMed
LinkOut - more resources
Full Text Sources